Problem
From the paper "United States v. Caronia A Victory for Free Speech vs. Off Label Promotion - Policy & Medicine", discuss the following:
• Whether or not the Caronia ruling can impact patient safety and risk, while at the same time benefiting the drug/device manufacturers.
• How can off label utilization of biomedical products approved by FDA benefit, as well as potential harmful in patient responsiveness to these products?